Acebright India Pharma is an API manufacturer based in India. It holds 4 active US drug master files across a filed portfolio of 7 molecules. Customs aggregates show $347 of exports covering 82 molecules to 4 destinations in 2025.
| Molecule | Regulators | Docs |
|---|---|---|
| Imatinib | US FDA | 2 |
| Dabigatran | US FDA | 1 |
| Dasatinib | SFDA (Saudi Arabia) | 1 |
| Erlotinib | SFDA (Saudi Arabia) | 1 |
| Imatinib Mesilate | SFDA (Saudi Arabia) | 1 |
| Lopinavir | US FDA | 1 |
| Tenofovir Disoproxil | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $347 | 4 |
| 2024 | Not reported | $22 | 1 |
| 2023 | Not reported | $1.2M | 12 |
| 2022 | Not reported | $12.1M | 18 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Acebright India Pharma comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.